Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Acelarin (NUC-1031) versus gemcitabine in metastatic pancreatic carcinoma
2014-004653-14Phase 3Unknown
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pracinostat in pancreatic cancer (PC) (2 arms), sponsored by The Clatterbridge Cancer Centre NHS Foundation Trust. Primary endpoint: Overall survival. Status: unknown.
02
Drugs
pracinostat
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2014-004653-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004653-14.